Creators of the first and only Long-term Implantable CGM.
Senseonics is a publicly traded medical technology company (NYSE: SENS) that develops the Eversense continuous glucose monitoring (CGM) system—the world's first and only long-term implantable CGM for people with diabetes. The Eversense 365 sensor is implanted under the skin and lasts up to 365 days, using fluorescence-based sensing technology paired with a removable smart transmitter and mobile app.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2025
Jan 2021
Mar 2016
Create a free account to see which investors have funded this company.
Create Free Account
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Outpatient mental health provider offering in-person and virtual therapy, psychiatry, and psychol...
Fitness wearable company offering a subscription-based health tracker that measures strain, recov...
Leading provider of diversified home and community-based health and pharmacy services to medicall...
operates in the healthcare industry focusing on biotechnology business
